What is it about?
Efficacy and tolerability of gemcitabine in a large series of patients with advanced adrenocortical carcinoma
Featured Image
Why is it important?
Adrenocortical carcinoma is rare and with limited therapeutic options for advanced stages. Gemcitabine is well tolerated and may be used as second-line treatment after failure of standard EDP-M scheme.
Read the Original
This page is a summary of: Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors, The Journal of Clinical Endocrinology & Metabolism, September 2017, Endocrine Society,
DOI: 10.1210/jc.2017-01624.
You can read the full text:
Contributors
The following have contributed to this page
